Patricia Véras Marrone

Mrs. Patricia Véras Marrone

Universidade de São Paulo, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2019 in IEEE Technology and Society Magazine
Verified
Journal Article
Closed access
JLJuliano Marcal Lopes
Juliano Marcal Lopes
Patricia Véras MarronePatricia Véras Marrone
Patricia Véras Marrone
SPSergio Luiz Pereira
Sergio Luiz Pereira
EDEduardo Mario Dias
Eduardo Mario Dias
Reports on major technologies and software programs in the health care industry and examines applications for their use, including 3D printing, artificial intelligence, deep learning, augmented reality, etc.

12 January 2023 in Economies
Verified
Journal Article
Open access
PDF file
Patricia Véras MarronePatricia Véras Marrone
Patricia Véras Marrone
FMFabio Rampazzo Mathias
Fabio Rampazzo Mathias
WBWanderley Bernardo
Wanderley Bernardo
MOMarina Orlandini
Marina Orlandini
MSMaria Carolina Andrade Serafim
Maria Carolina Andrade Serafim
EDEduardo Mario Dias
Eduardo Mario Dias
(1) Background: Any disturbance in the pharmaceutical supply chain (PSC) can disrupt the supply of medicines and affect the efficiency of health systems. Due to shortages in the global pharma supply chain over the past few years and the complex nature of free trade and its limitations when confronted by a major global health and humanitarian crisis, many countries have taken steps to mitigate the risks of disruption, including, for example, recommending the adoption of a plus one diversification approach, increasing safety stock, and nationalizing the medical supply chains. (2) Objective: To scope findings in the academic literature related to decision criteria to guide national policy decisions for the “Partial Nationalization of Pharmaceutical Supply Chain” (PNPSC) from the viewpoints of the three main stakeholders: industry, payers (government and health insurance), and patients. (3) Methods: These consist of a scoping review of the peer-reviewed literature. (4) Results: A total of 115 studies were included. For local manufacturing decisions, five criteria and 15 sub-criteria were identified. Weighting, decision-making, risk assessment, and forecasting were the main data analysis tools applied; (5) Conclusions: The findings could serve as a baseline for constructing PNPSC frameworks after careful adaptation to the local context.

11 May 2026 in JRSM Cardiovascular Disease
Verified
Journal Article
Closed access
Patricia Véras MarronePatricia Véras Marrone
Patricia Véras Marrone
MSMaria Lr Pinho Dias Scoton
Maria Lr Pinho Dias Scoton
MSMilana Santos
Milana Santos
FMFabio R Mathias
Fabio R Mathias
IMIrineu F Delfino Silva Massaia
Irineu F Delfino Silva Massaia
EDEduardo Mario Dias
Eduardo Mario Dias
Background: Implantable Medical Devices (IMDs) are essential for ensuring the quality of life in patients. They also play a crucial role in terms of the costs associated with surgical procedures, as well as incurring potential risks requiring continuous monitoring following implantation. Objective: The aim of this systematic review of public health intervention was to determine which countries collect data on the utilization of implantable cardiovascular medical devices (IMD-Cs), and how countries record the captured data. We identified parameters for comparing the use of IMD-Cs among countries that could serve as an example for Latin American countries. Method: A Rapid Systematic Review of the literature through a survey using three search engines was carried out between July and August 2024. Eligible studies measured the annual use of IMD-Cs based on nationwide data published between January 2014 and August 2024. Data were synthesized using tables and an analytical approach. Results: From 1602 identified publications, 23 studies measuring the use of IMD-Cs were selected. This made it possible to map the sites where national records repositories are located and the type of data held therein. Conclusions: Many countries collect countrywide information on IMD-Cs and use a variety of methods to register/record the data. There are substantial advantages for a country with IMD-C registries, including monitoring access to IMD-Cs; tracking the costs of the devices; assessing the levels of incorporation of relevant new technologies; and helping improve medical and nursing protocols.